Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372231 | 1.00 | CYP2D6 (0.42) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL862202 | 1.00 | CYP2D6 (0.42) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL3947286 | 0.97 | CYP2D6 (0.41) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL3947285 | 0.97 | CYP2D6 (0.41) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL20421795 | 0.97 | CYP2D6 (0.41) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL1543190 | 0.97 | L3MBTL3 (0.43) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL11942150 | 0.97 | L3MBTL3 (0.43) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3195988 | 0.97 | L3MBTL3 (0.43) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL15190812 | 0.95 | L3MBTL3 (0.41) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL22190785 | 0.95 | L3MBTL3 (0.41) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-118284610-A | Pyrazolotriazine derivatives as CDK9 inhibitors | 原真股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024068740-A1 | NOVEL CDK9 INHIBITORS | ORIGENIS GMBH (DE) | 2024-04-04 | — | — | WO | disclosed |
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023139164-A1 | CDK9 INHIBITORS | ORIGENIS GMBH (DE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023094310-A1 | PYRAZOLOTRIAZINE DERIVATIVES USEFUL AS CDK9 INHIBITORS | ORIGENIS GMBH (DE) | 2023-06-01 | — | — | WO | disclosed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-10988482-B2 | IRAK4 inhibitor and use thereof | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2021-04-27 | — | — | US | disclosed |
| CN-107531725-B | IRAK4 inhibitor and application thereof | 北京韩美药品有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2006018221-A1 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-02-02 | — | — | US | disclosed |
| EP-1599478-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6861422-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004076454-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988482-B2 | IRAK4 inhibitor and use thereof | IRAK4, IRAK1, IRAK2 | CYP2D6 4031/4885CYP2C19 4239/4885L3MBTL3 2351/4885 |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | CYP2D6 330/4885CYP2C19 301/4885L3MBTL3 4268/4885 |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | CYP2D6 13/4885CYP2C19 106/4885L3MBTL3 4854/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | CYP2D6 45/4885CYP2C19 219/4885L3MBTL3 1941/4885 |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | CYP2D6 21/4885CYP2C19 144/4885L3MBTL3 1953/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | CYP2D6 15/4885CYP2C19 73/4885L3MBTL3 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.